Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00027209 · ClinicalTrials.gov registry record · Phase 2
Hormone Replacement in Menopausal Women With Epilepsy
A Phase 2 study of Epilepsy and Menopause, sponsored by National Institute of Neurological Disorders and Stroke (NINDS).
- Completed
- Registry status
- Phase 2
- Development phase
- 125
- Enrollment target
- 1
- Study location
NCT00027209: Completed Phase 2 study of Epilepsy and Menopause, sponsored by National Institute of Neurological Disorders and Stroke (NINDS).
NCT00027209 is a Phase 2 study of Epilepsy and Menopause that has completed, run by National Institute of Neurological Disorders and Stroke (NINDS). The registered enrollment target is 125 participants, below the 952-participant average among 160 other Epilepsy trials with a reported enrollment target (87% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00027209, a Phase 2 study of Epilepsy and Menopause, has completed, sponsored by National Institute of Neurological Disorders and Stroke (NINDS).
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 125 participants
- Enrollment target
- 1
- Study location
Study Summary
The goal of this study is to evaluate the effect of synthetic hormone replacement therapy on anti-seizure medication levels, menopausal symptom relief, and seizure frequency and safety in menopausal women with epilepsy.
Interventions
- DRUG prempro
Study Locations (1)
New York
- New York Presbyterian Hospital-Weill Medical College of Cornell University, Comprehensive Epilepsy Center - New York
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 125 participants |
| Phase | Phase 2 |
What the finished NCT00027209 record still lists
NCT00027209 is an interventional study that assigns participants to a tested intervention. The registered 125 participants enrollment target is mid-sized for trials with a published cap, below the 952-participant average among 160 other Epilepsy trials with a reported enrollment target (87% lower).
The record links to 2 conditions, with Epilepsy appearing as the primary indexed condition, and to 1 intervention - of which prempro is the first listed.
NCT00027209 reports a single indexed study location in New York.
Frequently Asked Questions
What is clinical trial NCT00027209 about?
NCT00027209 is a clinical study titled "Hormone Replacement in Menopausal Women With Epilepsy". The goal of this study is to evaluate the effect of synthetic hormone replacement therapy on anti-seizure medication levels, menopausal symptom relief, and seizure frequency and safety in menopausal women with epilepsy.
What is the current status of trial NCT00027209?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 125 participants.
What conditions does trial NCT00027209 study?
This clinical trial studies the following conditions: Epilepsy, Menopause.
What interventions are being tested in trial NCT00027209?
The interventions under investigation include: prempro (DRUG).
Who is sponsoring clinical trial NCT00027209?
This trial is sponsored by National Institute of Neurological Disorders and Stroke (NINDS), which has 567 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00027209 being conducted?
This trial has 1 study location across New York. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Epilepsy
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT00027209's enrollment target sits among peer trials
125 46th of 160 higher than 115 of 160 other Epilepsy trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Epilepsy trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Stopping TSC Onset and Progression 2B: Sirolimus TSC Epilepsy Prevention Study
RECRUITING · Phase 2
-
A Long-term Study of the Safety and Effectiveness of RAP-219 in Adults With Focal Onset Seizures
RECRUITING · Phase 2
-
RNS System LGS Feasibility Study
ACTIVE NOT RECRUITING · Phase 2
-
Study of an External Responsive Neurostimulator System on Epileptiform Activity
COMPLETED · Phase 2
-
Abnormal Ventilatory Response to Carbon Dioxide: a Potential Biomarker for Seizure Induced Respiratory Depression & Modification by SSRI
COMPLETED · Phase 2
-
Pediatric Epilepsy Study in Subjects 1-24 Months
COMPLETED · Phase 2
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02717039 · 125 participants
Pharmacogenomics of Heparin-Induced Thrombocytopenia
- NCT02763033 · 125 participants · Phase 2
Dietary Manipulation of the Microbiome-metabolomic Axis for Mitigating GVHD in Allo HCT Patients
- NCT02793999 · 125 participants
Perinatal Brain Injury: Potential of Innovative NIRS to Optimize Hypothermia
- NCT03003299 · 125 participants · NA
PARTNER 3 Trial - Aortic Valve-in-Valve